Myeloma - Nascent Medical, LLC

Transcription

Myeloma
HittPackTM
Myeloma HittPackTM
Contents
I.
Disease and Treatment Information in Myeloma ................................................................................. 2
II.
Recent News Articles in Myeloma ......................................................................................................... 2
Medscape Medical News (free password required).................................................................................. 2
MedpageToday ......................................................................................................................................... 3
Reuters ...................................................................................................................................................... 4
III. Press Releases in Myeloma ................................................................................................................... 6
Eurekalert.org ........................................................................................................................................... 6
Newswise.com ........................................................................................................................................ 11
Google.com ............................................................................................................................................. 15
IV. US Food and Drug Administration Info on Myeloma .......................................................................... 17
Drugs@FDA Database ............................................................................................................................ 17
2011 Advisory Committee Meetings ....................................................................................................... 20
V.
Guidelines in Myeloma ........................................................................................................................ 20
National Guidelines Clearinghouse--Guidelines.gov ............................................................................... 20
National Comprehensive Cancer Network .............................................................................................. 23
American Society of Clinical Oncology .................................................................................................... 23
VI. Conferences and Medical Associations for Myeloma ......................................................................... 24
Conferences ............................................................................................................................................. 24
Medical Associations............................................................................................................................... 24
VII. Key Opinion Leaders in Myeloma ........................................................................................................ 24
VIII. Clinical Trials in Progress in Myeloma ................................................................................................. 25
IX. PubMed Search in Myeloma ............................................................................................................... 36
Randomized Controlled Trials ................................................................................................................. 36
Reviews ................................................................................................................................................... 39
Editorials ................................................................................................................................................. 54
Hitt Medical Writing, LLC © 2011
www.hittmedicalwriting.com
Page 1
Myeloma HittPackTM
I.
Disease and Treatment Information in Myeloma

National Cancer Institute - General Information About Multiple Myeloma/Other Plasma Cell
Neoplasms
http://www.cancer.gov/cancertopics/types/myeloma

American Cancer Society – Multiple Myeloma detailed guide
http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index

American Society of Clinical Oncology- Multiple Myeloma
Oncologist-approved cancer information from the American Society of Clinical Oncology
http://www.cancer.net/patient/Cancer+Types/Multiple+Myeloma

emedicine.medscape.com – Multiple Myeloma
http://emedicine.medscape.com/article/204369-overview
II.
Recent News Articles in Myeloma
Medscape Medical News (free password required)
http://www.medscape.com/; search term = myeloma; all results for the past 3 months.

Tandem Autologous-Allogeneic Stem-Cell Transplants for Myeloma Improve Survival Patients
with previously untreated multiple myeloma do better when they're given an autologous stemcell transplant followed by an allogeneic transplant ... News, Reuters Health
Information, July 2011

With New Induction Drugs for Multiple Myeloma, Still OK to Delay Stem Cell Transplant In
patients with multiple myeloma treated initially with new immunomodulatory drugs, delaying
stem cell transplantation won't affect overall survival, a ... News, Reuters Health
Information, September 2011

Bone Marrow Involvement Predicts Progression to Symptomatic Myeloma... make up at least
60% of the bone marrow, the odds of smoldering multiple myeloma progressing to symptomatic
myeloma rise dramatically, researchers report ... News, Reuters Health Information, August 2011

Surprise: Lenalidomide May Interact With P-Glycoprotein... properties, is a standard treatment
for initial and relapsed multiple myeloma. Temsirolimus, which has been approved for the
treatment of renal cell ... News, Medscape Medical News, August 2011
Page 2
Myeloma HittPackTM

Lenalidomide Has Positive Benefit/Risk Ratio, Says EMA... with dexamethasone for the secondline treatment of adults with multiple myeloma who have failed at least 1 previous therapy. The
review followed ... News, Medscape Medical News, September 2011

Johnson & Johnson Warns of Doxil (doxorubicin) Shortage... Boehringer Ingelheim and used to
treat ovarian cancer and multiple myeloma. Doxil is among a growing number of drugs made by
specialty drugmakers ... News, Reuters Health Information, July 2011

Incidence of Thromboembolic Events With Cisplatin Too High... Patients who receive either of
these drugs for the treatment of multiple myeloma have an 18% to 22% risk for thrombosis. In
fact, it is recommended that ... News, Medscape Medical News, September 2011

Bendamustine/rituximab Helpful in Refractory Leukemia... has been used in Germany for more
than 40 years to treat multiple myeloma, non-Hodgkin's lymphoma and solid cancers. It was
recently approved in ... News, Reuters Health Information, August 2011

Denosumab Approved in EU for Cancer With Bone Metastases... and in a third trial in patients
with other solid tumors or multiple myeloma and bone metastases (J Clin Oncol. 2011;29:11251132), denosumab was ... News, Medscape Medical News, July 2011

Is Benefit of Bortezomib in Follicular Lymphoma Worthwhile?... Oncology. Bortezomib was
originally licensed for use in multiple myeloma; last year, it's label was updated to include data
on survival benefit. ... News, Medscape Medical News, August 2011

Deaths From Prescription Opioids on the Rise... in 2007. Such deaths are now more common
than deaths from multiple myeloma, HIV, and alcoholic liver disease. Oxycodone Particularly
Dangerous A ... News, Medscape Medical News, August 2011
MedpageToday
http://www.medpagetoday.com/; search term = myeloma; all results for the past 3 months.
ECCO-ESMO: Study Finds Target for Multiple
Myeloma Treatment
9/28/2011
Russian researchers suggested here that a
molecular analysis of plasma cells from patients
with multiple myeloma might give clues about
when targeted therapies would be most
appropriate.
ECCO-ESMO: Bone Drug's Benefits Consistent in
Myeloma
9/28/2011
The survival and skeletal benefits of treatment
with an intravenous bisphosphonate remained
consistent across a population of patients with
multiple myeloma, subgroup analysis of a large
clinical trial showed.
ECCO-ESMO: Model May Predict Drug Success in
Page 3
Myeloma HittPackTM
ECCO-ESMO: Stem Cell Therapy Still Multiple
Myeloma Mainstay
9/28/2011
Although new drugs have proven effective in
multiple myeloma, results of a phase III study
confirmed that autologous stem cell
transplantation remains a therapeutic bedrock for
newly diagnosed disease, researchers found.
Myeloma...
9/28/2011
A modeling simulation based on interim reduction
in M-protein can predict outcomes in multiple
myeloma patients being treated with the
investigational drug pomalidomide, researchers
suggested here.
Lab Notes: Building a Better Knee
9/28/2011
Bortezomib is a proteasome inhibitor currently
used against multiple myeloma and lymphoma,
but, in vitro, it also blocks production of fibrotic
proteins involved in both pulmonary fibrosis and
scleroderma.
Reuters
www.reuters.com; search term = myeloma; all results for the past 3 months.
J&J sees continued supply shortages of cancer drug
... The injectable drug, which had annual global sales of about $500 million as of July, is used to treat
ovarian cancer and multiple myeloma. ...
Wed Sep 28, 2011 1:59am EDT
Celgene shares jump ahead of EU drug safety review
... It is approved in the United States and Europe, in combination with dexamethasone, to treat
patients with multiple myeloma who have failed at least one ...
Tue Sep 20, 2011 2:50pm EDT
UPDATE 1-Celgene shares jump ahead of EU drug safety review
... It is approved in the United States and Europe, in combination with dexamethasone, to treat
patients with multiple myeloma who have failed at least one ...
Page 4
Myeloma HittPackTM
Tue Sep 20, 2011 2:50pm EDT
MorphoSys Announces Clinical Milestone in Cancer Antibody Program ...
... rheumatoid arthritis, MOR208, which is in a Phase 1/2a trial for chronic lymphocytic leukemia and
MOR202, which is in a Phase 1/2a trial for multiple myeloma. ...
Wed Sep 14, 2011 1:31am EDT
Gene therapy shown to destroy leukemia tumors
... The results provide "a tumor-attack roadmap for the treatment of other cancers," including those
of the lung and ovaries as well as myeloma and melanoma ...
Wed Aug 10, 2011 2:26pm EDT
Revlimid side effects linked to protein in study
... LOS ANGELES, Aug 8 - An early-stage trial of Celgene Corp's <CELG.O> multiple myeloma drug
Revlimid has found that it interacts with another protein that ...
Mon Aug 8, 2011 4:00pm EDT
Celgene second quarter profit rises; ups 2011 forecast
... Sales of Revlimid, the company's drug to treat multiple myeloma and most important growth
driver, rose 35 percent to $795 million as physicians increasingly ...
Thu Jul 28, 2011 11:24am EDT
UPDATE 3-Celgene 2nd-qtr profit rises; ups 2011 forecast
... Sales of Revlimid, the company's drug to treat multiple myeloma and most important growth
driver, rose 35 percent to $795 million as physicians increasingly ...
Thu Jul 28, 2011 11:22am EDT
J&J warns doctors of Doxil cancer-drug shortage
... The injectable drug, which has annual global sales of about $500 million, is used to treat ovarian
cancer and multiple myeloma. ...
Thu Jul 21, 2011 5:06pm EDT
Biotech stocks outperformed the general markets
Page 5
Myeloma HittPackTM
... major conferences. Better outcomes were achieved with Revlimid maintenance in newly diagnosed
multiple myeloma patients. This news ...
Thu Jul 21, 2011 1:31am EDT
III. Press Releases in Myeloma
Eurekalert.org
www.eurekalert.org; search term = myeloma; first 20 results.
John Theurer Cancer Center among first clinical trial sites to join
landmark MMRF study
... of personalized treatments for multiple myeloma ... segments
and variations of multiple myeloma. The study is the centerpiece
... the centerpiece of the Multiple Myeloma Research
Foundation's (MMRF) Personalized ...
http://www.eurekalert.org/pub_releases/2011-09/jtccjtc092011.php- 11.6KB - Public Press Releases
65%
Novel approach scores first success against elusive cancer gene
... The results, achieved in multiple myeloma cells, offer a
promising strategy ... strategy for treating not only myeloma but
also many other cancer ... namesake of JQ1. In multiple
myeloma, MYC is hyperactive – constantly ordering ...
http://www.eurekalert.org/pub_releases/2011-09/dcinas090911.php- 10.1KB - Public Press Releases
67%
Moffitt Cancer Center researchers use new tool to counter
multiple myeloma drug resistance
... new tool to counter multiple myeloma drug resistance ...
individualized patient treatments for multiple myeloma. The
technique has potentially broader ... Multiple myeloma is an
incurable malignancy in ...
http://www.eurekalert.org/pub_releases/2011-09/hlmc-
67%
||||||||||||||||||||
20 Sep 11
Find Similar
Highlight
||||||||||||||||||||
09 Sep 11
Find Similar
Highlight
||||||||||||||||||||
09 Sep 11
Find Similar
Highlight
Page 6
Myeloma HittPackTM
mcc090911.php- 10.1KB - Public Press Releases
Subcutaneous injection of bortezomib A promising and safer
alternative to intravenous ...
... delivery in patients with multiple myeloma ... treatment in
patients with multiple myeloma (cancer of the bone marrow ...
newly diagnosed and relapsed multiple myeloma. As an
alternative to the ...
http://www.eurekalert.org/pub_releases/2011-04/lsio041511.php- 8.8KB - Public Press Releases
67%
||||||||||||||||||||
18 Apr 11
Find Similar
Highlight
Researchers sequence multiple myeloma genome in landmark
71%
||||||||||||||||||||
Nature study
23 Mar 11
... Researchers sequence multiple myeloma genome in landmark
Nature study ... Ph.D., Co-Chief, Multiple Myeloma John Theurer Find Similar
Cancer Center part ... complete genomic portrait of multiple
Highlight
myeloma, a highly aggressive blood cancer ...
http://www.eurekalert.org/pub_releases/2011-03/jtccrsm032111.php- 12.1KB - Public Press Releases
First look at the full multiple myeloma genome reveals new
68%
||||||||||||||||||||
insights, discoveries
23 Mar 11
... look at the full multiple myeloma genome reveals new insights,
discoveries ... 40 tumor genomes points multiple myeloma
Find Similar
research in new directions ... full genetic blueprint of multiple
Highlight
myeloma, a form of blood cancer ...
http://www.eurekalert.org/pub_releases/2011-03/biomfla032111.php- 14.0KB - Public Press Releases
The MMRF and John Theurer Cancer Center to host patient
70%
||||||||||||||||||||
symposium
17 Mar 11
... and workshops from leading multiple myeloma specialists ...
March 16, 2011) — The Multiple Myeloma Research Foundation Find Similar
(MMRF) and the ... Center, member of the Multiple Myeloma
Page 7
Myeloma HittPackTM
Research Consortium (MMRC), will host ...
http://www.eurekalert.org/pub_releases/2011-03/jtcctma031711.php- 11.5KB - Public Press Releases
Highlight
VCU Massey first to combine targeted agents to kill multiple
69%
||||||||||||||||||||
myeloma cells
10 Feb 11
... targeted agents to kill multiple myeloma cells ... novel
treatment strategy for multiple myeloma that pairs two targeted Find Similar
agents ... to demonstrate the synergistic, anti-myeloma effects of
Highlight
this combination regimen ...
http://www.eurekalert.org/pub_releases/2011-02/vcuvm021011.php- 10.9KB - Public Press Releases
Drug combination shows promise for newly diagnosed blood
67%
||||||||||||||||||||
cancer patients, study finds
09 Dec 11
... treat the blood cancer multiple myeloma may be effective as a
... line treatment of patients with myeloma, a type of cancer that Find Similar
... D., director of the multiple myeloma program at the University
Highlight
of ...
http://www.eurekalert.org/pub_releases/2010-12/uomhdcs120910.php- 9.7KB - Public Press Releases
Study identifies key molecules in multiple myeloma
72%
||||||||||||||||||||
... identifies key molecules in multiple myeloma ... often turned
26 Oct 10
off in multiple myeloma, a presently incurable cancer of ... leads
to the death of myeloma cells and could provide a ...
Find Similar
http://www.eurekalert.org/pub_releases/2010-10/osumHighlight
sik102610.php- 8.2KB - Public Press Releases
High response rates seen in phase-III trial of chemotherapy, new drug and stem
cells in ...
... new drug and stem cells in myeloma The ... to treating newly diagnosed multiple
myeloma has found that both treatments ... patients with newly diagnosed multiple
myeloma. ...
http://www.eurekalert.org/pub_releases/2010-10/esfm-hrr100910.php- 7.7KB -
67% ||||||||||||||||||||
10 Oct 10
Find Similar
Highlight
Page 8
Myeloma HittPackTM
Public Press Releases
TGen-Mayo Clinic study discovers role of DNA methylation in multiple myeloma
blood cancer
... of DNA methylation in multiple myeloma blood cancer ... Report finds
development of multiple myeloma is tied to 'hypomethylation' ... new ways of
treating multiple myeloma by targeting the multiple myeloma epigenome. This
study also emphasizes ...
http://www.eurekalert.org/pub_releases/2010-09/ttgr-tcs092910.php- 11.6KB Public Press Releases
69% ||||||||||||||||||||
New discovery brings hope to treatment of incurable blood cancer
... Multiple myeloma is one of the most ... development and progression of multiple
myeloma. The study was done in ... Using large cohorts of myeloma patients the
researchers have identified ...
http://www.eurekalert.org/pub_releases/2010-07/uu-ndb071610.php- 6.5KB Public Press Releases
64% ||||||||||||||||||||
Arizona Myeloma Network presents 'Special Award' to TGen president
... Arizona Myeloma Network presents 'Special Award' to ... July 1, 2010 — The
Arizona Myeloma Network (AzMN) has presented a ... in the 2nd annual Arizona
Myeloma Network Race for Hope for ...
http://www.eurekalert.org/pub_releases/2010-07/ttgr-amn063010.php- 9.1KB Public Press Releases
68% ||||||||||||||||||||
New myeloma drug shows promise in early testing
... New myeloma drug shows promise in early ... appears promising in treating
multiple myeloma, a type of blood cancer ... chemotherapies approved to treat
multiple myeloma, a cancer that arises in ...
http://www.eurekalert.org/pub_releases/2010-06/uomh-nmd060710.php- 8.5KB Public Press Releases
69% ||||||||||||||||||||
30 Sep 10
Find Similar
Highlight
16 Jul 10
Find Similar
Highlight
01 Jul 10
Find Similar
Highlight
07 Jun 10
Find Similar
Highlight
64% ||||||||||||||||||||
Vertebroplasty: Integral to treating back pain in blood marrow cancer patients
... fractures in those with multiple myeloma, says largest study to date ... fractures in
Page 9
Myeloma HittPackTM
patients with multiple myeloma, a blood cancer, shows that ... the complicated
treatment of multiple myeloma, an incurable (yet treatable) cancer ...
http://www.eurekalert.org/pub_releases/2010-03/soir-vit030410.php- 11.5KB Public Press Releases
15 Mar 10
Drug shows positive responses, low side-effects in multiple myeloma
... low side-effects in multiple myeloma ... adverse side effects among multiple
myeloma patients in a phase II ... with relapsed or resistant multiple myeloma who
have received one to ...
http://www.eurekalert.org/pub_releases/2009-12/uotm-dsp_1120509.php- 9.8KB Public Press Releases
69% ||||||||||||||||||||
Multiple myeloma patients experience high response rate with new 3-drug
combination
... Multiple myeloma patients experience high response rate ... patients newly
diagnosed with multiple myeloma, a cancer of white blood ... be highly effective in
multiple myeloma patients who had relapsed or ...
http://www.eurekalert.org/pub_releases/2009-12/dci-mmp120409.php- 8.7KB Public Press Releases
68% ||||||||||||||||||||
Find Similar
Highlight
07 Dec 09
Find Similar
Highlight
05 Dec 09
Find Similar
Highlight
72% ||||||||||||||||||||
IMF teleconference: An advance look at multiple myeloma at ASH 2009
... An advance look at multiple myeloma at ASH 2009 ... Emerging myeloma
24 Nov 09
therapies set stage for treating ... for Aptium Oncology, the International Myeloma
Foundation's International Myeloma Working Group and the Myeloma Committee Find Similar
of the Southwest Oncology ...
Highlight
http://www.eurekalert.org/pub_releases/2009-11/bp-ita112409.php- 7.7KB - Public
Press Releases
Lower-dose dexamethasone can be used to treat newly diagnosed myeloma
... used to treat newly diagnosed myeloma ... mainstay of therapy for multiple
myeloma. However, a study published Online ... in patients with newly diagnosed
myeloma; and is thus a viable ...
http://www.eurekalert.org/pub_releases/2009-10/l-ldc102009.php- 9.4KB - Public
Press Releases
72% ||||||||||||||||||||
21 Oct 09
Find Similar
Highlight
Page 10
Myeloma HittPackTM
Newswise.com
www.newswise.com; search term = myeloma, sorted by date. Results 1 through 20 of 258
Blood Pressure Drugs May Lengthen Lives of Melanoma Patients
Ohio State University
2011-09-20
Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in
slowing the progression of certain serious cancers, based on a new study.
Novel Approach Scores First Success Against Elusive Cancer Gene
Dana-Farber Cancer Institute
2011-09-09
Dana-Farber researchers successfully disrupted the function of the gene MYC by tampering with the
gene's "on" switch and growth signals in multiple myeloma cells, offering promising strategy for
treating myeloma and other cancers driven by the MYC gene.
Researchers Use New Tool To Counter Multiple Myeloma Drug Resistance
Moffitt Cancer Center
2011-09-09
Moffitt Cancer Center researchers, and colleagues, are pioneering promising research utilizing a
monitoring technology that could provide a better understanding of acquired drug resistance and
assist in clinical decision-making for developing individualized patient treatments for multiple
myeloma.
Researchers at UT Southwestern find way to help donor adult blood stem cells overcome transplant
rejection
UT Southwestern Medical Center
2011-08-03
Findings by UT Southwestern Medical Center researchers may suggest new strategies for successful
donor adult stem cell transplants in patients with blood cancers such as leukemia, lymphoma and
myeloma.
It’s in the Sugar: Mayo Clinic Shows How Metabolism Affects Stem Cell Cultivation
Page 11
Myeloma HittPackTM
Mayo Clinic
2011-08-01
Providing new insight into the biomechanics of regenerative medicine, researchers at Mayo Clinic
have shown how cellular metabolism facilitates stem cell procurement from regular tissue.
Specialized Regulatory T Cell Stifles Antibody Production Centers
University of Texas M. D. Anderson Cancer Center
2011-07-25
A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies
launched by the immune system to attack invaders, a team led by scientists at The University of
Texas MD Anderson Cancer Center reported online in the journal Nature Medicine.
Statewide Cord Blood Bank Celebrates Grand Opening at UAMS
University of Arkansas for Medical Sciences
2011-07-19
Celebrating the grand opening of the Cord Blood Bank of Arkansas at the University of Arkansas for
Medical Sciences (UAMS) today, Brian and Jennifer Odle told how the use of cord blood gave their
18-month-old daughter a new lease on life.
Patient Partnership: A Powerful Shift in Health Care Delivery at UAMS Myeloma Institute
University of Arkansas for Medical Sciences
2011-06-23
A new model of care developed for patients at the Myeloma Institute for Research and Therapy at
the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience,
lower costs and better patient outcomes.
Device Could Improve Harvest of Stem Cells from Umbilical Cord Blood
Johns Hopkins University
2011-06-20
A graduate student team has invented a system to significantly boost the number of stem cells
collected from a newborn’s umbilical cord and placenta, so that many more patients with leukemia,
lymphoma and other blood disorders can be treated.
Page 12
Myeloma HittPackTM
NewYork-Presbyterian/Weill Cornell Research Presented at American Society of Clinical Oncologists
Meeting
NewYork-Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
2011-06-03
Among those presenting at this year's American Society of Clinical Oncologists meeting are
physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The meeting
takes place June 3–7, at McCormick Place, Chicago.
Prepared Patient: Watchful Waiting — When Treatment Can Wait
Health Behavior News Service
2011-06-01
When it comes to certain medical conditions, delaying treatment while regularly monitoring the
progress of disease — a strategy doctors refer to as “watchful waiting,” active surveillance or
expectant management — may benefit some patients more than a rush to pharmaceutical or
surgical options.
Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients
2011-05-31
Landmark study of personalized therapy may lead to a “flood of new agents.”
Treatment with Lenalidomide After Stem-Cell Transplant Improves Multiple Myeloma Survival,
Reduces Risk of Progression
Roswell Park Cancer Institute
2011-05-13
Philip McCarthy, Jr., MD, of Roswell Park Cancer Institute presented data from a CALGB trial at the
International Myeloma Workshop. Patients receiving maintenance lenalidomide therapy had higher
survival rate and lower risk of disease progression.
Health Literacy Tests Underutilized; May Improve Elderly Cancer Patients’ Care and Outcomes
2011-04-29
Page 13
Myeloma HittPackTM
MD Anderson nurse recommends health practitioners assess health literacy to overcome barrier to
quality care.
AACR Awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students
American Association for Cancer Research (AACR)
2011-03-25
The American Association for Cancer Research will recognize 27 recipients of the AACR-Thomas J.
Bardos Science Education Award for Undergraduate Students at the AACR 102nd Annual Meeting
2011, held here from April 2 to 6.
First Look at the Full Multiple Myeloma Genome Reveals New Insights, Discoveries
Dana-Farber Cancer Institute
2011-03-21
Broad Institute and Dana-Farber scientists have unveiled the most comprehensive picture to date of
the full genetic blueprint of multiple myeloma. The study yielded insights into the events that lead to
this form of cancer and could influence the direction of research.
Mouse Cancer Genome Unveils Genetic Errors in Human Cancers
Washington University in St. Louis
2011-03-21
By sequencing the genome of a mouse with cancer, researchers at Washington University School of
Medicine in St. Louis have uncovered mutations that also drive cancer in humans. The investigators
are the first to sequence a mouse cancer genome, and their research is reported online March 23 in
the Journal of Clinical Investigation.
New Hope for Baby Boomers with Leukemia and Lymphoma
Loyola University Health System
2011-02-17
As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell
transplants to leukemia and lymphoma patients who previously were too old to qualify.
Researchers Pinpoint How One Cancer Gene Functions
Mayo Clinic
Page 14
Myeloma HittPackTM
2011-01-31
For several decades, researchers have been linking genetic mutations to diseases ranging from
cancer to developmental abnormalities. What hasn’t been clear, however, is how the body’s genome
sustains such destructive glitches in the first place. Now a team of Mayo Clinic scientists and
collaborators provide an unprecedented glimpse of a little-understood gene, called MMSET,
revealing how it enables disease-causing mutations to occur. The findings appear in the current issue
of Nature.
Prototype Drug Targets Metabolism, Halts Disease That Limits Bone Marrow Transplantation
University of Michigan
2011-01-27
A prototype drug already shown to hold promise for treating autoimmune disorders like lupus,
arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone
marrow transplantation, research at the University of Michigan and the University of Florida shows.
Google.com
Search term = “myeloma press releases”. First 10 results returned
1. Multiple Myeloma Press Releases
www.ereleases.com/pr/tag/multiple-myelomaCached
You +1'd this publicly. Undo
NEWTOWN, Pa., March 23, 2010 — When Edwin Hill was diagnosed with Multiple Myeloma his first
reaction was disbelief. He was young, healthy, in the prime of ...
2. multiple myeloma News - FierceBiotech Research
www.fiercebiotechresearch.com/tags/multiple-myelomaCached
9 Apr 2007 – multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference
Call on Second Quarter 2011 Financial Results ...
3. multiple myeloma News - FierceVaccines
www.fiercevaccines.com/tags/multiple-myelomaCached
Page 15
Myeloma HittPackTM
5 May 2011 – multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference
Call on Second Quarter 2011 Financial Results ...
4. multiple myeloma News - FierceBiotech
www.fiercebiotech.com/tags/multiple-myelomaCached
multiple myeloma Press Releases. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second
Quarter 2011 Financial Results ...
5. multiple myeloma - Online Public Relations - Online Press Releases ...
www.widepr.com/search.html?q=multiple+myelomaCached
10 Dec 2010 – Search. press release search. multiple myeloma Press Releases. Page 1 / 1. June 30,
2011 -. Business Press Release · Yorkville Advisors, LLC ...
6. Cancer - Lymphoma Society
www.thecancerinfo.com/lymphoma/lymphoma_society/
Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. (Press Releases) The Leukemia
& Lymphoma Society Congratulates Corina Morariu, ...
7. Cancer - Leukemia Lymphoma Society
www.thecancerinfo.com/lymphoma/leukemia_lymphoma_society/Cached
Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. (Press Releases ...
Show more results from thecancerinfo.com
8. myeloma News - FiercePharma
www.fiercepharma.com/tags/myelomaCached
Page 16
Myeloma HittPackTM
17 Oct 2008 – myeloma Press Releases. European Commission Adopts European Medicines Agency's
( EMA) Recommendation to Lift the Suspension of the Marketing ...
9. lymphoma
top-health.smsprikol.com/letter-l/lymphoma.htmlCached
Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. ... (Press Releases) The Leukemia &
Lymphoma Society Offers Program on Childhood Leukemia and ...
10. Leukemia
www.eastcairn.com/Diseases/leukemia.htmlCached
Fighting leukemia, lymphoma, Hodgkin's disease and myeloma. ... Press Releases) The Leukemia &
Lymphoma Society and the Leukemia Research Fund of Canada ...
IV. US Food and Drug Administration Info on Myeloma
Drugs@FDA Database
Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu
October 2011
None
September 2011
Drug Name
and
FDA Appl. #
PUR-WASH
(NDA # 022305)
Active
Ingredients
NDA Chem. Review Company Approval
Type *
ClassifiDate
cation **
PURIFIED WATER
5
S
NIAGARA 09/01/2011
PHARMA
Page 17
Myeloma HittPackTM
INC
LAMIVUDINE;
TENOFOVIR
DISOPROXIL
FUMARATE;
NEVIRAPINE
(NDA # 202171)
LAMIVUDINE; TENOFOVIR
DISOPROXIL FUMARATE;
NEVIRAPINE
LAMIVUDINE;
ZIDOVUDINE
(NDA # 201151)
LAMIVUDINE; ZIDOVUDINE
4
S
MATRIX 09/08/2011
LABS LTD
CIPLA
09/22/2011
LIMITED
MEMANTINE
MEMANTINE
HYDROCHLORIDE HYDROCHLORIDE
(NDA # 200155)
TORRENT 09/27/2011
PHARMS
CLOBETASOL
PROPIONATE
(NDA # 201402)
PERRIGO 09/27/2011
ISRAEL
CLOBETASOL PROPIONATE
August 2011
GEMCITABINE
(NDA # 200795)
GEMCITABINE
HYDROCHLORIDE
3
S
HOSPIRA
INC
08/04/2011
ROSUVASTATIN
ZINC
(NDA # 202172)
ROSUVASTATIN ZINC
2
S
WATSON
LABS INC
08/04/2011
COMPLERA
(NDA # 202123)
EMTRICITABINE;
RILPIVIRINE; TENOFOVIR
DISOPROXIL FUMARATE
4
P
GILEAD
SCIENCES
INC
08/10/2011
ZELBORAF
(NDA # 202429)
VEMURAFENIB
1
P
HOFFMAN 08/17/2011
N LA
ROCHE
Page 18
Myeloma HittPackTM
ADCETRIS
(BLA # 125388)
BRENTUXIMAB VEDOTIN
SEATTLE 08/19/2011
GENETICS
ADCETRIS
(BLA # 125399)
BRENTUXIMAB VEDOTIN
SEATTLE 08/19/2011
GENETICS
FIRAZYR
(NDA # 022150)
ICATIBANT ACETATE
1
P
SHIRE
ORPHAN
THERAP
08/25/2011
NUCYNTA ER
(NDA # 200533)
TAPENTADOL
HYDROCHLORIDE
3
S
ORTHO
MCNEIL
JANSSEN
08/25/2011
XALKORI
(NDA # 202570)
CRIZOTINIB
1
P
PFIZER
08/26/2011
July 2011
Drug Name
and
FDA Appl. #
Active
Ingredients
NDA Chem. Review Company
Type *
Classification **
Approval
Date
ARCAPTA NEOHALER INDACATEROL
(NDA # 022383)
MALEATE
1
S
NOVARTIS
07/01/2011
XARELTO
(NDA # 022406)
RIVAROXABAN
1
S
JOHNSON AND
JOHNSON
07/01/2011
BRILINTA
(NDA # 022433)
TICAGRELOR
1
S
ASTRAZENECA LP 07/20/2011
HEPARIN SODIUM
(NDA # 201370)
HEPARIN
SODIUM
5
S
PFIZER
07/21/2011
HEPARIN SODIUM
PRESERVATIVE FREE
HEPARIN
SODIUM
5
S
PFIZER
07/21/2011
Page 19
Myeloma HittPackTM
(NDA # 201370)
EPINEPHRINE
(NDA # 201739)
EPINEPHRINE
INTELLIJECT INC. 07/29/2011
2011 Advisory Committee Meetings
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm
V.
Guidelines in Myeloma
National Guidelines Clearinghouse--Guidelines.gov
www.guidelines.gov; Search criteria = “myeloma” all years, sorted by relevance, first 20 listed
1.
2.
Thalidomide in multiple myeloma. 2010 Jan 20. NGC:008036
Compare
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View Selected
all guidelines by the developer(s)
Bortezomib in multiple myeloma and lymphoma. 2006 Apr 3 (revised 2008 Nov Compare
24). NGC:007275
Selected
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.].
View all guidelines by the developer(s)
Page 20
Myeloma HittPackTM
3.
Guidelines on the diagnosis and management of multiple myeloma 2005. 2006 Compare
Feb. NGC:005100
Selected
British Committee for Standards in Haematology - Professional Association.
4.
American Society of Clinical Oncology 2007 clinical practice guideline update
on the role of bisphosphonates in multiple myeloma. 2002 Sep 1 (revised 2007
Jun 10). NGC:005670
American Society of Clinical Oncology - Medical Specialty Society. View all
guidelines by the developer(s)
Compare
Selected
5.
Lenalidomide for the treatment of multiple myeloma in people who have
received at least one prior therapy. 2009 Jun. NGC:007383
National Institute for Health and Clinical Excellence (NICE) - National
Government Agency [Non-U.S.]. View all guidelines by the developer(s)
Compare
Selected
6.
Multiple myeloma (MM). 2001 Dec 27 (revised 2007 May 30). NGC:005818
Finnish Medical Society Duodecim - Professional Association. View all guidelines
by the developer(s)
Compare
Selected
7.
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG):
guidelines for the investigation of newly detected M-proteins and the
management of monoclonal gammopathy of undetermined significance
(MGUS). 2009 Oct. NGC:007594
Compare
Selected
8.
Guideline for the use of imaging in the management of myeloma. 2007 Apr.
NGC:006178
Compare
Selected
9.
Treatment for anemia with erythropoietic agents in patients with non-myeloid Compare
hematological malignancies: a clinical practice guideline. 2007 Jan 17.
Selected
NGC:005525
Page 21
Myeloma HittPackTM
10.
The prophylactic use of filgrastim in patients with hematological
malignancies. 2009 Sep 23. NGC:007885
Compare
Selected
11.
Haematological cancer. In: Suspected cancer in primary care: guidelines for
investigation, referral and reducing ethnic disparities. 2009 Sep 1.
NGC:007554
New Zealand Guidelines Group - Nonprofit Organization. View all guidelines by
the developer(s)
Compare
Selected
12.
American Society of Clinical Oncology/American Society of Hematology
clinical practice guideline update on the use of epoetin and darbepoetin in
adult patients with cancer. 2002 Apr 18 (revised 2010 Nov 20). NGC:008178
American Society of Clinical Oncology - Medical Specialty Society; American
Society of Hematology - Medical Specialty Society. View all guidelines by the
developer(s)
Compare
Selected
13.
Metastatic malignant disease of unknown primary origin. Diagnosis and
management of metastatic malignant disease of unknown primary origin.
2010 Jul. NGC:008074
National Collaborating Centre for Cancer - National Government Agency [NonU.S.]. View all guidelines by the developer(s)
Compare
Selected
14.
Stem cell transplantation in adults: recommendations. 2009 Jan. NGC:007225
Compare
Selected
15.
American Cancer Society guidelines on nutrition and physical activity for
cancer prevention: reducing the risk of cancer with healthy food choices and
physical activity. 2002 Mar (revised 2006 Sep). NGC:006082
American Cancer Society - Disease Specific Society. View all guidelines by the
developer(s)
Compare
Selected
16.
Guidelines on the diagnosis and management of solitary plasmacytoma of
bone, extramedullary plasmacytoma and multiple solitary plasmacytomas:
2009 update. 2004 Mar (revised 2009 Mar). NGC:007591
Compare
Selected
Page 22
Myeloma HittPackTM
17.
ACR Appropriateness Criteria® metastatic bone disease. 1995 (revised 2009).
NGC:007773
American College of Radiology - Medical Specialty Society. View all guidelines
by the developer(s)
Compare
Selected
18.
Treatment of anemia with erythropoietic agents in patients with cancer –
adaption/adoption of ASH-ASCO guidelines. 2010 Jan 15. NGC:008037
Compare
Selected
19.
Metastatic spinal cord compression. Diagnosis and management of adults at
risk of and with metastatic spinal cord compression. 2008 Nov. NGC:007194
National Collaborating Centre for Cancer - National Government Agency [NonU.S.]. View all guidelines by the developer(s)
Compare
Selected
20.
ACR Appropriateness Criteria® follow-up of malignant or aggressive musculoskeletal
tumors. 1998 (revised 2011). NGC:008460
American College of Radiology - Medical Specialty Society. View all guidelines by the
developer(s)
National Comprehensive Cancer Network
Free password required
www.nccn.org
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Multiple Myeloma
http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
American Society of Clinical Oncology
www.asco.org
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the role of
bisphosphonates in multiple myeloma
http://jco.ascopubs.org/content/25/17/2464.full.pdf
Page 23
Myeloma HittPackTM
VI. Conferences and Medical Associations for Myeloma
Conferences

American Society of Hematology annual meeting http://hematology.org/Meetings/AnnualMeeting/

International Myeloma Workshop http://www.myeloma-paris2011.com/

Lymphoma and Myeloma 2011: An International Congress on Hematologic Malignancies
hhttp://www.lymphomaandmyeloma.com/2011/index.html

American Society of Clinical Oncology (ASCO) annual meeting http://chicago2011.asco.org/

Annual European Society of Medical Oncology (ESMO) Congress http://www.esmo.org/

Annual Multiple Myeloma Conference
http://www.lls.org/aboutlls/chapters/wi/patienteducation/multiplemyelomaconf/
Medical Associations

American Society of Hematology (ASH)

International Myeloma Foundation

Multiple Myeloma Research Foundation (MMRF)

American Cancer Society (ACS)

American Society of Clinical Oncology (ASCO)

National Cancer institute (NCI)

Association of Cancer Online Resources

European Hematology Association

Myeloma Euronet
VII. Key Opinion Leaders in Myeloma
A listing of key opinion leaders (KOLs) in myeloma who have participated in recent CME activities
available online. Where possible, the sponsor information has been listed.

Sagar Lonial, MD, Associate Professor; Vice Chair of Clinical Affairs, Hematology and Medical
Oncology; Director, Translational Research B-Cell Malignancy Program, Winship Cancer Institute,
Emory University, Atlanta, Georgia. Served as an advisor or consultant for: Bristol-Myers Squibb
Company; Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals
Corporation; Onyx Pharmaceuticals, Inc. Served as a speaker or a member of a speakers bureau
for: Merck & Co., Inc.

Jonathan L. Kaufman, MD, Assistant Professor, Hematology and Medical Oncology, Associate
Director, Hematology and Medical Oncology Fellowship Program, Winship Cancer Institute,
Emory University, Atlanta, Georgia. Served as an advisor or consultant for: Millennium
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Keryx
Page 24
Myeloma HittPackTM
Biopharmaceuticals Received grants for clinical research from: Celgene Corporation; Merck &
Co., Inc.

Antonio Palumbo, MD, Chief, Myeloma Unit, Division of Hematology, University of Turin, Turin,
Italy. Served as an advisor or consultant for: Celgene Corporation; Janssen Biotech, Inc.

Sergio Giralt, MD, Chief, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering
Cancer Center, New York, New York. Served as an advisor or consultant for: Millennium
Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Onyx
Pharmaceuticals, Inc.; Genzyme Pharmaceuticals; Amgen Inc.

Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple Myeloma Center, Dana Farber
Cancer Institute; Kraft Family Professor of Medicine, Harvard Medical School, Boston,
Massachusetts. Served as an advisor or consultant for: Bristol-Myers Squibb Company;
Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation;
Merck & Co., Inc.; Onyx Pharmaceuticals, Inc. Owns stocks, stock options, or bonds from:
Acetylon.

Ruben Niesvizky, MD, Associate Professor of Medicine; Director, Myeloma Service, Division of
Hematology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, New
York. Served as an advisor or consultant for: Millennium Pharmaceuticals, Inc.; Celgene
Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.

Paul G Richardson, MD, Clinical Director, Jerome Lipper Center for Multiple Myeloma; Associate
Professor of Medicine, Harvard Medical School, Boston, Massachusetts. Served as an advisor or
consultant for: Millennium Pharmaceuticals, Inc.; Celgene Corporation; Novartis Pharmaceuticals
Corporation

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma and Bone Cancer
Research, West Hollywood, California. Served as an advisor or consultant for: Millennium
Pharmaceuticals, Inc.; Celgene Corporation; Cephalon, Inc.; OrthoBiotech Products, L.P.; Novartis
Pharmaceuticals Corporation; Amgen Inc.; CuraGen; Cytogen Corporation; Seattle Genetics, Inc.
Received grants for clinical research from: Millennium Pharmaceuticals, Inc.; Celgene
Corporation; Cephalon, Inc.; Novartis Pharmaceuticals Corporation; Amgen Inc.; CuraGen;
Cytogen Corporation; Seattle Genetics, Inc.; Pfizer Inc.; ZIOPHARM Oncology, Inc. Served as a
speaker or a member of a speakers bureau for: Millennium Pharmaceuticals, Inc.; Celgene
Corporation; Cephalon; OrthoBiotech Products, L.P.; Novartis Pharmaceuticals Corporation.

Sundar Jagannath, MD, Director of the Multiple Myeloma Program, Professor of Medicine
(Hematology and Medical Oncology), The Tisch Cancer Institute, Mount Sinai School of Medicine,
New York. Supported by an educational grant from Onyx Pharmaceuticals, Inc.

Morie A. Gertz, MD, Division of Hematology, Mayo Clinic, Rochester, MN. Member of the
Millennium Advisory Board, received research support from Genzyme, and received honoraria
from Millennium, Easi, Celgene, and Amgen.
VIII. Clinical Trials in Progress in Myeloma
Page 25
Myeloma HittPackTM
Clinical trials.gov
Search criteria- myeloma | Open Studies | Exclude Unknown | Phase III, IV
63 of 63 studies listed
1
2
3
4
5
6
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto
Transplantation in Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Biological: MAGE-A3; Biological: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory
or Relapsed Refractory Multiple Myeloma
Condition:
Multiple Myeloma
Intervention:
Drug: pomalidomide
Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose
Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and
Refractory Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: pomalidomide; Drug: dexamethasone
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly
Diagnosed Multiple Myeloma
Condition:
Multiple Myeloma and Plasma Cell Neoplasm
Interventions:
Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating
Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition:
Interventions:
Drug: cyclophosphamide; Drug: melphalan; Procedure: autologous
hematopoietic stem cell transplantation
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in
Patients With Multiple Myeloma
Page 26
Myeloma HittPackTM
7
8
9
10
11
12
Conditions:
Multiple Myeloma; Auto Stem Cell Transplant
Intervention:
Drug: Bortezomib
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple
Myeloma Patients
Condition:
Multiple Myeloma
Interventions:
Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamet
hasone
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple
Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Panobinostat; Drug: Bortezomib; Drug: Dexamethasone; Drug: Placeb
o
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously
Untreated Multiple Myeloma
Condition:
Interventions:
Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple
Myeloma
Conditions:
Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Me
tastases; Multiple Myeloma Bone Lesions
Interventions:
Drug: Denosumab; Drug: Zoledronic acid
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line
Treatment for Myeloma
Condition:
Multiple Myeloma
Intervention:
Procedure: Single ASCT with Thalidomide maintenance
Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple
Myeloma
Conditions:
Multiple Myeloma; Compression Fracture of Vertebral Column
Page 27
Myeloma HittPackTM
Intervention:
13
14
15
16
17
18
19
Procedure: Kyphoplasty/Vertebral Augmentation (Device-StabiliT)
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN
0702)
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in
Patients With Newly Diagnosed Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Bortezomib, Melphalan, Prednisone (VMP); Drug: 1 or 2 cycle(s) HDM (Hi
gh Dose Melphalan); Drug: 2 cycles of Bortezomib, Lenalidomide,
Dexamethasone (VRD)
Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
Condition:
Multiple Myeloma
Intervention:
Other: tandem autologous transplantation
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple
Myeloma
Condition:
Interventions:
Drug: lenalidomide; Other: clinical observation
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Condition:
Multiple Myeloma
Interventions:
Drug: zoledronic acid; Other: No treatment control
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide; Drug: Dexamethasone
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being
Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Condition:
Multiple Myeloma
Page 28
Myeloma HittPackTM
Intervention:
20
21
22
23
24
25
26
Other: Any MMY treatment
Autologous Transplant for Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Th
alidomide; Drug: Melphalan; Biological: Granulocytecolony stimulating factor; Drug: Dexamethasone
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Condition:
Relapsed/Refractory Multiple Myeloma
Interventions:
Drug: plitidepsin + dexamethasone; Drug: dexamethasone
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple
Myeloma
Conditions:
Fatigue; Multiple Myeloma
Interventions:
Drug: armodafinil; Drug: Placebo
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple
Myeloma
Condition:
Multiple Myeloma
Intervention:
Drug: Lenalidomide
Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide
and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Condition:
Relapsed Multiple Myeloma
Interventions:
Drug: Dexamethasone; Drug: Lenalidomide; Drug: Carfilzomib
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With
Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Thalidomide; Drug: Melphalan+Prednisolone
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Condition:
Multiple Myeloma
Page 29
Myeloma HittPackTM
Interventions:
27
28
29
30
31
32
Drug: Bortezomib,Pirarubicin,Dexamethasone; Drug: Thalidomide,Pirarubicin,D
examethasone
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in
Patients With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Placebo, Velcade and dexamethasone; Biological: Siltuximab, Velcade an
d dexamethasone
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants
and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Conditions:
Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple M
yeloma
Interventions:
Drug: melphalan; Drug: amifostine trihydrate; Procedure: peripheral blood
stem cell
transplantation; Genetic: fluorescence in situ hybridization; Procedure: bone
marrow ablation with stem cell support
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newlydiagnosed Myeloma Patients
Condition:
Multiple Myeloma
Intervention:
Drug: velcade
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or
Multiple Myeloma With Bone Involvement
Conditions:
Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplas
m; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complica
tions
Intervention:
Drug: zoledronic acid
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in
Page 30
Myeloma HittPackTM
MM Patients up to Age 65
33
34
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: A
utologous Stem Cell Transplant
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose
Chemotherapy
Condition:
Multiple Myeloma
Interventions:
Drug: Emend; Drug: Placebo
Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple
Myeloma
Condition:
Multiple Myeloma
Interventions:
Procedure: Autologous bone marrow transplantation; Procedure: Allogeneic bo
ne marrow transplantation
35
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
36
Condition:
Multiple Myeloma
Interventions:
Drug: bortezomib (Velcade); Drug: cyclophosphamide; Drug: G-CSF
Imaging Young Myeloma (IMAgerie JEune Myélome)
37
38
Condition:
Multiple Myeloma
Interventions:
Procedure: PET scan; Procedure: MRI
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple
Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: carfilzomib; Drug: Best Supportive Care
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus
Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Condition:
Multiple Myeloma
Interventions:
Drug: Melphalan, Prednisone, Lenalidomide; Drug: Cyclophosphamide, Prednis
one, Lenalidomide; Drug: Lenalidomide, dexamethasone
Page 31
Myeloma HittPackTM
39
40
41
Busulfan Plus Melphalan Versus Melphalan
Condition:
Myeloma
Interventions:
Drug: Busulfan; Drug: Melphalan; Other: Questionnaire; Drug: GCSF; Drug: High Dose Melphalan; Procedure: Stem cell transplant
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2)
Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Condition:
Multiple Myeloma
Interventions:
Drug: Cyclophosphamide; Drug: Lenalidomide; Drug: Dexamethasone; Drug:
Melphalan
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma
(MM) Patients
Condition:
Multiple Myeloma
Intervention:
42
43
44
45
Pseudohyponatremia of Multiple Myeloma is True Hyponatremia
Condition:
Hyponatremia of Multiple Myeloma
Intervention:
Other: blood test
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated
With Lenalidomide
Condition:
Refractory Multiple Myeloma
Interventions:
Drug: plerixafor; Biological: filgrastim
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the
Initial Myeloma up to 65 Years
Conditions:
Patients Newly Diagnosed With Symptomatic Multiple
Myeloma; Patients Aged up to 65 Years; Progression Free Survival Prolongatio
n; Time to Progression; Overall Survival
Intervention:
Drug: Lenalidomide, Bortézomib
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone
Tumors for the Palliation of Pain
Page 32
Myeloma HittPackTM
46
47
48
49
50
51
Conditions:
Bone Metastases; Multiple Myeloma
Interventions:
Device: ExAblate 2000; Device: Sham
Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy
Condition:
Chronic Renal Failure With Uremic Nephropathy
Interventions:
Drug: Cyclophosphamide + Bortezomib + Dexamethasone
regimen; Drug: Bortezomib +Dexamethasone regimen; Device: HCO group; D
evice: conventional high-flux dialyzer
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly
Diagnosed, Previously Untreated Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide; Drug: Dexamethasone; Biological: Elotuzumab
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without
Elotuzumab in Relapsed or Refractory Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Dr
ug: Dexamethasone (IV); Biological: Elotuzumab
The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose
Melphalan in the Treatment of Multiple Myeloma
Condition:
Multiple Myeloma
Interventions:
Drug: Lenalidomide, Dexamethasone; Drug: Lenalidomide, Dexamethasone, PB
SCT
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound
(MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and
Multiple Myeloma
Conditions:
Bone Cancer; Secondary Malignant Neoplasm of Bone; Pain
Interventions:
Device: Exablate treatment; Radiation: Radiation
Personalized Information or Basic Information in Helping Patients Make Decisions About
Participating in a Clinical Trial
Page 33
Myeloma HittPackTM
52
53
54
55
Conditions:
Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorder
s; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma
and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Mye
loproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
Other: educational intervention
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant
Conditions:
Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblasti
c Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplas
m; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm
s; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions:
Other: educational intervention; Other: laboratory biomarker analysis; Other:
questionnaire administration; Other: survey administration; Procedure: psych
osocial assessment and care; Procedure: stress management therapy; Proced
ure: support group therapy
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex)
Followed by ASCT
Condition:
Multiple Myeloma
Intervention:
Drug: bortezomib + dexamethasone
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously
Untreated Systemic Light-Chain Amyloidosis
Condition:
Interventions:
Drug: bortezomib; Drug: dexamethasone; Drug: melphalan
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By
Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition:
Interventions:
Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure:
autologous hematopoietic stem cell transplantation
Page 34
Myeloma HittPackTM
56
57
58
59
60
61
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive Tcells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related,
Haploidentical Donor
Conditions:
Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma;
Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention:
Biological: Donor lymphocyte preparation depleted of host functional
alloreactive T-cells
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the
Treatment of Low Grade B Cell Malignancies
Conditions:
Multiple Myeloma; Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma; Non Hodgkin's Lymphoma; Waldenstroms; Mantle Cell Lympho
ma
Interventions:
Drug: Fludarabine; Radiation: Total Body Irradiation; Other: Infusion of Stem
Cells
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following
Nonmyeloablative Allogeneic Stem Cell Transplantation
Conditions:
Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Multiple Myeloma
Interventions:
Radiation: Total Body Irradiation; Drug: Fludarabine; Procedure: Recipient Leu
kocyte Infusion
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Conditions:
Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions:
Drug: Plerixafor; Drug: Filgrastim
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic
Pain
Condition:
Cancer
Interventions:
Drug: ketamine hydrochloride; Other: pharmacogenomic studies; Other: quest
ionnaire administration; Procedure: assessment of therapy complications; Pro
cedure: quality-of-life assessment
Exercise During Chemotherapy for Patients With Hematological Malignancies
Page 35
Myeloma HittPackTM
62
63
Conditions:
Hematological Diseases; Hematological Malignancies
Interventions:
Other: Aerobic exercise; Behavioral: Fatigue counseling
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Condition:
Cancer
Interventions:
Dietary Supplement: Vitamin D; Dietary Supplement: Calcium
A Trial for Systemic Light-chain (AL) Amyloidosis
Condition:
AL Amyloidosis
Intervention:
Drug: BMDex
IX. PubMed Search in Myeloma
http://www.ncbi.nlm.nih.gov/pubmed/
Search = myeloma, published in the last 180 days, English only
Randomized Controlled Trials
Results: 7
1.
Safety and efficacy of zoledronic acid in multiple myeloma.
Tanimoto T, Matayoshi T, Yagasaki F, Takeuchi K, Kami M.
Lancet. 2011 Jun 25;377(9784):2178. No abstract available.
PMID:
21704866
[PubMed - indexed for MEDLINE]
Related citations
2.
Safety and efficacy of zoledronic acid in multiple myeloma.
Kyrgidis A, Tzellos TG.
Page 36
Myeloma HittPackTM
Lancet. 2011 Jun 25;377(9784):2177-8. No abstract available.
PMID:
21704864
Related citations
3.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple
myeloma: a randomised, phase 3, non-inferiority study.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak
T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W,
Harousseau JL.
Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.
PMID:
21507715
Related citations
4.
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation
and prognostication in multiple myeloma.
Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L,
Oriol A, Teruel AI, de Paz R, Laraña JG, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F,
Bladé J, Orfao A, Lahuerta JJ, San Miguel JF.
J Clin Oncol. 2011 Apr 20;29(12):1627-33. Epub 2011 Mar 14.
PMID:
21402611
Related citations
Page 37
Myeloma HittPackTM
5.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with
bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple
myeloma.
Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimopoulos MA, Kropff M,
Spicka I, Petrucci MT, Samoilova OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS,
Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF.
Eur J Haematol. 2011 May;86(5):372-84. doi: 10.1111/j.1600-0609.2011.01599.x. Epub 2011 Mar 30.
PMID:
21366694
Related citations
6.
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated
liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ.
Cancer. 2011 Aug 15;117(16):3758-62. doi: 10.1002/cncr.25937. Epub 2011 Feb 15.
PMID:
21328327
Related citations
7.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple
myeloma patients undergoing stem cell mobilization.
Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore D, Specchia G, De
Paolis MR, Mazza P, Pietrantuono G, Petrini M.
Leuk Res. 2011 Jul;35(7):899-903. Epub 2010 Dec 4.
PMID:
Page 38
Myeloma HittPackTM
21134693
Related citations
Reviews
Results: 43
1.
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC.
Oncology (Williston Park). 2011 Jun;25(7):594, 596. Review. No abstract available.
PMID:
21888257
Related citations
2.
Multiple myeloma precursor disease: current clinical and epidemiological insights and future
opportunities.
Landgren O, Korde N.
Oncology (Williston Park). 2011 Jun;25(7):589-90. Review. No abstract available.
PMID:
21888256
Related citations
3.
Page 39
Myeloma HittPackTM
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering
multiple myeloma (SMM).
Kyle RA, Buadi F, Rajkumar SV.
Oncology (Williston Park). 2011 Jun;25(7):578-86. Review.
PMID:
21888255
Related citations
4.
Multiple myeloma: diagnosis and orthopaedic implications.
Scharschmidt TJ, Lindsey JD, Becker PS, Conrad EU.
J Am Acad Orthop Surg. 2011 Jul;19(7):410-9. Review.
PMID:
21724920
Related citations
5.
Fibroblast growth factors and their receptors in cancer.
Wesche J, Haglund K, Haugsten EM.
Biochem J. 2011 Jul 15;437(2):199-213. Review.
PMID:
21711248
Related citations
Page 40
Myeloma HittPackTM
6.
Translational development of vaccination strategies in follicular NHL.
Sakamaki I, Qin H, Kwak LW.
Best Pract Res Clin Haematol. 2011 Jun;24(2):295-304. Epub 2011 May 6. Review.
PMID:
21658625
Related citations
7.
Notch-ing from T-cell to B-cell lymphoid malignancies.
Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R.
Cancer Lett. 2011 Sep 1;308(1):1-13. Review.
PMID:
21652011
Related citations
8.
Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM, Slassi M, Kay LE, Schimmer AD.
J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. Epub 2011 May 23. Review.
PMID:
21606441
Related citations
Page 41
Myeloma HittPackTM
9.
Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with
angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature.
Ahsanuddin AN, Brynes RK, Li S.
Int J Clin Exp Pathol. 2011 Apr;4(4):416-20. Epub 2011 Apr 18. Review.
PMID:
21577327
Free PMC Article
Free full text Related citations
10.
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect
with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel
combination regimens.
Zangari M, Fink L, Zhan F, Tricot G.
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. Epub 2011 Apr 8. Review.
PMID:
21575928
Related citations
11.
Management of multiple myeloma in pregnancy: strategies for a rare challenge.
Kasenda B, Rückert A, Farthmann J, Schilling G, Schnerch D, Prömpeler H, Wäsch R, Engelhardt M.
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):190-7. Epub 2011 Apr 9. Review.
PMID:
Page 42
Myeloma HittPackTM
21575923
Related citations
12.
Guidelines for the diagnosis and management of multiple myeloma 2011.
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G,
Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in
Haematology (BCSH) and UK Myeloma Forum.
Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14.
Review. No abstract available.
PMID:
21569004
Related citations
13.
Differential diagnosis of Schnyder corneal dystrophy.
Weiss JS, Khemichian AJ.
Dev Ophthalmol. 2011;48:67-96. Epub 2011 Apr 26. Review.
PMID:
21540632
Related citations
14.
γδ T-cell immunotherapy for lung cancer.
Yoshida Y, Nakajima J, Wada H, Kakimi K.
Page 43
Myeloma HittPackTM
Surg Today. 2011 May;41(5):606-11. Epub 2011 May 1. Review.
PMID:
21533930
Related citations
15.
A clinical perspective of IL-1β as the gatekeeper of inflammation.
Dinarello CA.
Eur J Immunol. 2011 May;41(5):1203-17. doi: 10.1002/eji.201141550. Review.
PMID:
21523780
Related citations
16.
Guidelines for supportive care in multiple myeloma 2011.
Snowden JA, Ahmedzai SH, Ashcroft J, D'Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G,
Bird JM; Haemato-oncology Task Force of British Committee for Standards in Haematology and UK
Myeloma Forum.
Br J Haematol. 2011 Jul;154(1):76-103. doi: 10.1111/j.1365-2141.2011.08574.x. Epub 2011 Apr 22.
Review.
PMID:
21517805
Related citations
17.
Page 44
Myeloma HittPackTM
Vertebra plana in an adolescent caused by multiple myeloma: a case report and review of the literature.
Greenleaf RM, Ricciardella LF, Latona CR, Sangimino MJ.
J Bone Joint Surg Am. 2011 Apr 20;93(8):e37. Review. No abstract available.
PMID:
21508272
Related citations
18.
Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil
recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell
mobilization.
Keating GM.
Drugs. 2011 Apr 16;71(6):679-707. doi: 10.2165/11206870-000000000-00000. Review.
PMID:
21504247
Related citations
19.
Cervical epidural plasmacytoma presenting as ascending paraparesis.
Lourbopoulos A, Ioannidis P, Balogiannis I, Stavrinou P, Koletsa T, Karacostas D.
Spine J. 2011 May;11(5):e1-4. Epub 2011 Apr 17. Review.
PMID:
21498133
Related citations
Page 45
Myeloma HittPackTM
20.
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older
patients?
Palumbo A, Mateos MV, Bringhen S, San Miguel JF.
Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.
PMID:
21497966
Related citations
21.
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Pozzi S, Raje N.
Oncologist. 2011;16(5):651-62. Epub 2011 Apr 14. Review.
PMID:
21493759
Related citations
22.
Recurrence of secondary glomerular disease after renal transplantation.
Ponticelli C, Moroni G, Glassock RJ.
Clin J Am Soc Nephrol. 2011 May;6(5):1214-21. Epub 2011 Apr 14. Review.
PMID:
21493742
Related citations
Page 46
Myeloma HittPackTM
23.
Advances in imaging and the management of myeloma bone disease.
Terpos E, Moulopoulos LA, Dimopoulos MA.
J Clin Oncol. 2011 May 10;29(14):1907-15. Epub 2011 Apr 11. Review.
PMID:
21483016
Related citations
24.
Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Hervé AL, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, Jean-Luc H, Nikhil M, Stéphane M.
PMID:
21482986
Related citations
25.
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
Moreau P, Avet-Loiseau H, Harousseau JL, Attal M.
PMID:
21482979
Related citations
Page 47
Myeloma HittPackTM
26.
Future directions of next-generation novel therapies, combination approaches, and the development of
personalized medicine in myeloma.
Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG.
PMID:
21482978
Related citations
27.
How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and
opinions.
Offidani M, Corvatta L, Morabito F, Gentile M, Musto P, Leoni P, Palumbo A.
Expert Opin Investig Drugs. 2011 Jun;20(6):779-93. Epub 2011 Apr 7. Review.
PMID:
21470070
Related citations
28.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma
(SMM): novel biological insights and development of early treatment strategies.
Korde N, Kristinsson SY, Landgren O.
Blood. 2011 May 26;117(21):5573-81. Epub 2011 Mar 25. Review.
PMID:
21441462
Page 48
Myeloma HittPackTM
Related citations
29.
Pomalidomide therapy for myeloma.
Schey S, Ramasamy K.
Expert Opin Investig Drugs. 2011 May;20(5):691-700. Epub 2011 Mar 18. Review.
PMID:
21413906
Related citations
30.
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Kumar S.
Curr Hematol Malig Rep. 2011 Jun;6(2):104-12. Review.
PMID:
21394431
Related citations
31.
Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications
for cancer immunotherapy by adoptive T cell transfer.
Corthay A, Lorvik KB, Bogen B.
Scand J Immunol. 2011 Jun;73(6):527-30. doi: 10.1111/j.1365-3083.2011.02558.x. Review.
PMID:
21388431
Page 49
Myeloma HittPackTM
Related citations
32.
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Mateos MV, San-Miguel J.
PMID:
21347656
Related citations
33.
New immunomodulatory drugs in myeloma.
Lacy MQ.
PMID:
21327565
Related citations
34.
Bisphosphonates in oncology.
Coleman RE, McCloskey EV.
Bone. 2011 Jul;49(1):71-6. Epub 2011 Feb 21. Review.
PMID:
21320652
Page 50
Myeloma HittPackTM
Related citations
35.
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
Dinarello CA.
Blood. 2011 Apr 7;117(14):3720-32. Epub 2011 Feb 8. Review.
PMID:
21304099
Related citations
36.
Plasma cell leukemia.
Albarracin F, Fonseca R.
Blood Rev. 2011 May;25(3):107-12. Epub 2011 Feb 3. Review.
PMID:
21295388
Related citations
37.
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau
JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P; European
Myeloma Network.
Leukemia. 2011 May;25(5):749-60. Epub 2011 Feb 4.
PMID:
Page 51
Myeloma HittPackTM
21293488
Related citations
38.
Consensus recommendations for standard investigative workup: report of the International Myeloma
Workshop Consensus Panel 3.
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D,
Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H,
Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus
Panel 3.
Blood. 2011 May 5;117(18):4701-5. Epub 2011 Feb 3.
PMID:
21292778
Related citations
39.
Consensus recommendations for risk stratification in multiple myeloma: report of the International
Myeloma Workshop Consensus Panel 2.
Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK,
Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV,
San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2.
PMID:
21292777
Related citations
40.
Page 52
Myeloma HittPackTM
Consensus recommendations for the uniform reporting of clinical trials: report of the International
Myeloma Workshop Consensus Panel 1.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson
P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J,
Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop
Consensus Panel 1.
PMID:
21292775
Related citations
41.
Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
Jantunen E, Fruehauf S.
Bone Marrow Transplant. 2011 May;46(5):627-35. Epub 2011 Jan 10. Review.
PMID:
21217789
Related citations
42.
Teratogenic effects of thalidomide: molecular mechanisms.
Ito T, Ando H, Handa H.
Cell Mol Life Sci. 2011 May;68(9):1569-79. Epub 2011 Jan 5. Review.
PMID:
21207098
Page 53
Myeloma HittPackTM
Related citations
43.
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, AvetLoiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.
Cancer Treat Rev. 2011 Jun;37(4):266-83. Epub 2010 Sep 21. Review.
PMID:
20863623
Related citations
Editorials
Results: 3
1.
Identification of genetic parameters associated with disease progression in plasma cell myeloma.
Bacher U, Binder M.
Leuk Res. 2011 Sep 14. [Epub ahead of print] No abstract available.
PMID:
21924493
[PubMed - as supplied by publisher]
Related citations
2.
Protein Z concentration in multiple myeloma patients.
Page 54
Myeloma HittPackTM
Bolkun L, Piszcz J, Oleksiuk J, Luksza E, Galar M, Szumowska A, Kloczko J.
Thromb Res. 2011 Aug 23. [Epub ahead of print] No abstract available.
PMID:
21868070
[PubMed - as supplied by publisher]
Related citations
3.
Humbling snapshots.
Kellerman PS.
Am J Kidney Dis. 2011 Jun;57(6):A21-3. No abstract available.
PMID:
21601122
Related citations
Page 55

Myeloma - Nascent Medical, LLC

Transcription

Similar documents

Evening Event Schedule

Understanding your MULTIPLE MYELOMA LAB TESTS

PHOTOS AND ME

Understanding MGUS and Smoldering Multiple Myeloma

as a PDF

Pain and myeloma

Multiple Myeloma: Patient Handbook